Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation*

Cyclin dependent kinases (CDKs) are key regulators of the cell cycle progression and therefore constitute excellent targets for the design of anticancer agents. Most of the inhibitors identified to date inhibit kinase activity by interfering with the ATP-binding site of CDKs. We recently proposed that the protein/protein interface and conformational changes required in the molecular mechanism of CDK2-cyclin A activation were potential targets for the design of specific inhibitors of cell cycle progression. To this aim, we have designed and characterized a small peptide, termed C4, derived from amino acids 285–306 in the α5 helix of cyclin A. We demonstrate that this peptide does not interfere with complex formation but forms stable complexes with CDK2-cyclin A. The C4 peptide significantly inhibits kinase activity of complexes harboring CDK2 in a competitive fashion with respect to substrates but does not behave as an ATP antagonist. Moreover, when coupled with the protein transduction domain of Tat, the C4 peptide blocks the proliferation of tumor cell lines, thereby constituting a potent lead for the development of specific CDK-cyclin inhibitors.

[1]  L. Johnson,et al.  The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.

[2]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[3]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[4]  L. Johnson,et al.  Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.

[5]  H Strohmaier,et al.  A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. , 2001, Molecular cell.

[6]  H. Kaneto,et al.  Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide , 2004, Nature Medicine.

[7]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[8]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[9]  H. Gali-Muhtasib,et al.  Modulating cell cycle: current applications and prospects for future drug development. , 2002, Current cancer drug targets.

[10]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[11]  M. Malumbres,et al.  Cell cycle deregulation: a common motif in cancer. , 2003, Progress in cell cycle research.

[12]  D. Fesquet,et al.  Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism. , 1997, Biochemistry.

[13]  A. Fersht,et al.  The Development of a CDK2-Docking Site Peptide that Inhibits p53 and Sensitizes Cells to Death , 2004, Cell cycle.

[14]  Ivo Tews,et al.  Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. , 2002, Biochemistry.

[15]  J. H. Wang,et al.  Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. , 1993, The Journal of biological chemistry.

[16]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[17]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[18]  R. Brent,et al.  An artificial cell-cycle inhibitor isolated from a combinatorial library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Lane,et al.  Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. , 2003, Current medicinal chemistry. Anti-cancer agents.

[20]  S. Morris.  Molecular clocks: Defusing the Cambrian ‘explosion’? , 1997, Current Biology.

[21]  M. Bogoyevitch,et al.  The Critical Features and the Mechanism of Inhibition of a Kinase Interaction Motif-based Peptide Inhibitor of JNK* , 2004, Journal of Biological Chemistry.

[22]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[23]  P. Jeffrey,et al.  Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.

[24]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[25]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Hunt,et al.  The crystal structure of cyclin A. , 1995, Structure.

[27]  D. Morgan,et al.  Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2 , 1995, Molecular and cellular biology.

[28]  H. Koeppen,et al.  Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. , 2003, Cancer research.

[29]  A. Huwe,et al.  Small molecules as inhibitors of cyclin-dependent kinases. , 2003, Angewandte Chemie.

[30]  John A. Tainer,et al.  Kinetic Mechanism of Activation of the Cdk2/Cyclin A Complex , 2002, The Journal of Biological Chemistry.

[31]  C. Swanton.  Cell-cycle targeted therapies. , 2004, The Lancet. Oncology.